Sanofi has stopped a pivotal clinical trial of venglustat in autosomal dominant polycystic kidney disease (ADPKD) for futility. The setback comes months after venglustat failed a phase 2 Parkinson’s disease trial but still leaves Sanofi with shots on goal.

When it comes to cancer screening, an already stressful process is often exacerbated by the possibility of undergoing an unnecessary and painful biopsy or, even worse, having an early-stage case go completely undetected.

The dream of a device converting nonverbal amyotrophic lateral sclerosis (ALS) patients’ brainwaves into speech could finally become a reality now that a neural signal processing platform designed to do just that has received regulatory clearance in Europe.

The smartwatch on your wrist already reminds you to get more steps in throughout the day, alerts you to new emails and even takes regular pulse readings. But its insights aren’t only skin-deep: According to the results of a long-term study, physical data collected by wearables can be directly linked to physiological changes typically diagnosed through clinical testing.

After serving as its exclusive distributor for years, Olympus is picking up a minimally invasive therapy for benign prostatic hyperplasia (BPH)—as well as its manufacturer—to expand its urologic portfolio to treat the widespread condition.

A phase 3 clinical trial of sugemalimab has met its primary endpoint. CStone Pharmaceuticals, which offloaded rights to the anti-PD-L1 antibody to EQRx and Pfizer last year, enrolled patients with stage 3 non-small cell lung cancer (NSCLC) patients in the study.

For Amgen, Lumakras started with a Polaroid—well, a crystallographic image or X-ray of the molecular structure that makes up the KRAS protein. But for the sake of simplicity, a picture inspired the development of the soon-to-be blockbuster drug.

Current standard-of-care hormone therapy can only go so far in treating metastatic prostate cancer until the body develops resistance, but new research from the Cleveland Clinic suggests a new pathway that could make tumors respond to treatments once again.

Magenta Therapeutics is losing its chief medical officer and head of R&D John Davis, M.D., with his last day coming July 30.

The COVID-19 pandemic put next-generation sequencing technology to the test—and GenapSys’ portable sequencer, for one, passed with flying colors.